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Cytokines play essential roles in innate and adaptive immunity. However, excess cytokines
or dysregulation of cytokine signaling will cause a variety of diseases, including allergies,
autoimmune diseases, inﬂammation, and cancer. Most cytokines utilize the so-called Janus
kinase–signal transducers and activators of transcription pathway. This pathway is nega-
tively regulated by various mechanisms including suppressors of cytokine signaling (SOCS)
proteins. SOCS proteins bind to JAK or cytokine receptors, thereby suppressing further
signaling events. Especially, suppressor of cytokine signaling-1 (SOCS1) and SOCS3 are
strong inhibitors of JAKs, because these two contain kinase inhibitory region at the N-
terminus. Studies using conditional knockout mice have shown that SOCS proteins are
key physiological as well as pathological regulators of immune homeostasis. Recent stud-
ies have also demonstrated that SOCS1 and SOCS3 are important regulators of helper T
cell differentiation and functions. This review focuses on the roles of SOCS1 and SOCS3
in T cell mediated inﬂammatory diseases.
Keywords: cytokine, signal transduction, immunity, STAT, helperT cell
THE CIS/SOCS FAMILY
Cytokines play essential roles in the development, differentiation,
and functionof myeloid and lymphoid cells. Someof them, includ-
ing interleukins, interferons (IFNs), and hematopoietic growth
factors, activate the Janus kinase (JAK)–signal transducers and
activators of the transcription (STAT) pathway (O’Shea et al.,
2002; Adamson et al., 2009). In this pathway, cytokine binding
results in receptor oligomerization, which initiates the activation
of JAK kinases (JAK1, JAK2, JAK3, and Tyk2). The activated JAKs
phosphorylate the receptor cytoplasmic domains, which creates
docking sites for SH2-containing signaling proteins, including
STATs. It is now known that a large number of cytokines, growth
factors, and hormonal factors activate JAK and/or STAT proteins.
The CIS/suppressors of cytokine signaling (SOCS) family of
proteins is one of the major mechanisms for regulations of
cytokine signaling (Endo et al., 1997; Kubo et al., 2003; Yoshimura
et al., 2007). The ﬁrst member of the family discovered is CIS,
cytokine-inducible SH2 protein (Yoshimura et al., 1995). This
molecule was identiﬁed by subtraction as an immediate-early gene
induced by erythropoietin (EPO). CIS is found to be a negative-
feedback regulator of the STAT5 pathway; binding to the phos-
phorylated tyrosine residues of cytokine receptors through the
SH2 domain, thereby masking STAT5 docking sites. CIS is a very
speciﬁc negative regulator of STAT5, and was conﬁrmed in vivo
by generating CIS transgenic mice (Matsumoto et al., 1999). The
second member, suppressor of cytokine signaling-1/JAK-binding
protein (SOCS1/JAB) was identiﬁed by three groups by differ-
ent methods (Endo et al., 1997; Naka et al., 1997; Starr et al.,
1997). We have isolated SOCS1/JAB as a JAK-binding protein, and
subsequently, we showed that SOCS1/JAB strongly inhibited JAK
tyrosine kinase activity.
At the time of their discovery, the SOCS proteins were rec-
ognized as an important mechanism in the negative regulation
of the cytokine-JAK–STAT pathway, but recent studies using
gene-disrupted mice have revealed that they play additional unex-
pected and important roles in many immunological processes
(Chinen et al., 2011; Hiwatashi et al., 2011; Takahashi et al., 2011;
Tamiya et al., 2011), atherosclerosis (Taleb et al., 2009), metabo-
lism (Mori et al., 2004; Torisu et al., 2007), and cancer (Yoshida
et al., 2004; Ogata et al., 2006a,b; Hiwatashi et al., 2011). In this
review, we will focus on the recent progress of SOCS studies on
inﬂammation and helper T cell differentiation.
THE CIS/SOCS FAMILY
OVERVIEW
The SOCS proteins and CIS (also known as CISH) protein
comprise a family of intracellular proteins (Yasukawa et al.,
2003; Yoshimura et al., 2007; Tamiya et al., 2011). There are
eight CIS/SOCS family proteins: CIS, SOCS1, SOCS2, SOCS3,
SOCS4, SOCS5, SOCS6, and SOCS7, each of which has a central
SH2 domain, an amino-terminal domain of variable length and
sequence, and a carboxy-terminal 40-amino-acid module known
as the SOCS box (Figure 1 left; Masuhara et al., 1997).
In addition, both SOCS1 and SOCS3 can inhibit JAK tyro-
sine kinase activity directly through their kinase inhibitory region
(KIR). KIR has been proposed to function as a pseudosubstrate
that is essential for the suppression of cytokine signals (Yasukawa
et al., 1999). The SH2 domain of SOCS3 does not have a high
afﬁnity to the activation loop of JAKs yet the KIR of SOCS3 has a
higher afﬁnity to the kinase domain of JAK2 than that of SOCS1
(Sasaki et al., 1999). Because the receptors to which SOCS3 binds
mostly activate STAT3, SOCS3 is an inhibitor that is relatively
speciﬁc to STAT3. SOCS3 also inhibits STAT4, which is activated
by IL-12 (Yamamoto et al., 2003). However, because SOCS3 does
not bind to the IL-10 receptor, SOCS3 cannot inhibit IL-10 sig-
naling. Therefore, IL-10 induces a robust and prolonged STAT3
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FIGURE 1 |The structure and function of SOCS proteins. (left) Schematic
structure of the CIS/SOCS family proteins. The SOCS box is conserved in all
CIS/SOCS family proteins. SOCS1 and SOCS3 contain a unique kinase
inhibitory region (KIR) immediately upstream of the central SH2 domain,
which is proposed to function as a pseudosubstrate. Other SOCS
box-containing proteins are illustrated. (right) Mechanism of suppression by
CIS, SOCS1, and SOCS3. All of these are induced by cytokine stimulation. CIS
binds to the STAT5 activating receptors, thereby suppressing further
activation of STAT5 and inducing degradation of the receptor. SOCS1 binds to
JAKs, and SOCS3 binds to the receptor through the SH2 domain, but both
inhibit JAK activity through KIR. These complexes may be degraded by
ubiquitination and proteasomal degradation recruited through the SOCS box.
activation, whereas IL-6-mediated STAT3 activation is transient
in macrophages. This is an important mechanism to distinguish
the anti-inﬂammatory activity of IL-10 and inﬂammatory activity
of IL-6 (Yasukawa et al., 2003).
SOCS1 and SOCS3 inhibit not only STATs but also other
signaling pathways such as Ras/ERK and PI3K, which affect
cell-proliferation, survival, and differentiation (Lu et al., 2006;
Madonna et al., 2008). Interestingly, SOCS3 is tyrosine phospho-
rylated upon cytokine or growth factor stimulation, and phospho-
rylated Y221 of SOCS3 interacts with p120-RasGAP, resulting in
a sustained activation of ERK. Although SOCS proteins inhibit
growth factor responses, tyrosine phosphorylation of SOCS3 can
ensure cell survival and proliferation through the Ras pathway
(Cacalano et al., 2001).
THE SOCS BOX AND UBIQUTINATION
The SOCS box is also found in other miscellaneous proteins
(Figure 1, left). The SOCS box interacts with elongin B and elon-
gin C, Cullins, and the RING-ﬁnger-domain-only protein RBX2
(which recruits E2 ubiquitin-transferase; Kamizono et al., 2001;
Kamura et al., 2004). VHL (von Hippel–Lindau) gene product,
whose gene product is the principal negative regulator of hypoxia-
inducible factor has been shown to bind to SOCS1 and induces
the degradation of Jak2. Chuvash polycythemia-associated VHL
mutants have altered afﬁnity for SOCS1 and do not engage with
and degrade phosphorylated JAK2 (Russell et al., 2011). These
results indicate that CIS/SOCS family proteins, as well as other
SOCS box-containing molecules, function as E3 ubiquitin ligases
and mediate the degradation of proteins that are associated with
these family members through their N-terminal regions (Figure 1,
left).
The central SH2 domain determines the target of each SOCS
and CIS protein. The SH2 domain of SOCS1 directly binds to the
activation loop of JAKs (Yasukawa et al., 1999). The SH2 domains
of CIS, SOCS2, and SOCS3 bind to phosphorylated tyrosine
residues on activated cytokine receptors (Kubo et al., 2003). SOCS3
binds to gp130-related cytokine receptors, including the phospho-
rylated tyrosine 757 (Tyr757) residue of gp130, the Tyr800 residue
of IL-12 receptor β2, and Tyr985 of the leptin receptor (Bjorbak
et al., 2000; Sasaki et al., 2000; Schmitz et al., 2000; Lehmann et al.,
2003; Yamamoto et al., 2003). Thus, SOCS3 in the brain has been
implicated in leptin-resistance (Mori et al., 2004; Zhang et al.,
2008). SOCS molecules bind to several tyrosine phosphorylated
proteins, including Mal (TLR signaling; Kobayashi et al., 2006)
and IRS1/2 (insulin signaling; Torisu et al., 2007). Thus, SOCS
proteins generally induce the degradation of the target molecules
by binding through the SH2 domain and ubiquitination through
the SOCS box (Figure 1, right).
SOCS AND INFLAMMATION
SOCS1 AND TISSUE INFLAMMATION
Although SOCS1 knockout (KO) mice are normal at birth, they
exhibit stunted growth and die within 3weeks of birth, with acti-
vation of peripheral T cells, necrosis of the liver, and macrophage
inﬁltration of major organs (Marine et al., 1999). The neonatal
defects exhibited by SOCS1−/− mice appear to occur primarily as a
result of unbridled IFNγ signaling, since SOCS1−/− mice that also
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lack the IFNγ gene or the IFNγ receptor gene do not die neona-
tal (Alexander et al., 1999). Since SOCS1/Rag2-double knockout
(DKO) mice survived much longer, SOCS1 has been thought to
be an important negative regulator of T cells. This is conﬁrmed
by analyzing T cell-speciﬁc SOCS1-conditional KO (cKO) mice
(Tanaka et al., 2008). T cell speciﬁc SOCS1 cKO mice developed
several inﬂammatory diseases with high levels of IFNγ.
In addition, SOCS1 has been demonstrated to be involved in
the suppression of inﬂammation by regulating innate immune
cells and non-immune cells. Using liver-speciﬁc SOCS1 cKO mice,
we demonstrated that SOCS1 deletion in hepatocytes enhanced
concanavalin A (ConA)-induced hepatitis due to enhanced pro-
apoptotic signals, including STAT1 and JNK, in the SOCS1-
deﬁcient liver (Torisu et al., 2008). SOCS1 deletion in NKT cells
also enhanced sensitivity to ConA-induced hepatitis. However,
the number of iNKT cells was drastically decreased but that of
type II NKT cells was increased by SOCS1 deﬁciency (Hashimoto
et al., 2011). The mechanism of imbalance between type I and
type II NKT cells by SOCS1 deﬁciency remains to be clariﬁed.
Deﬁciency of SOCS1 in macrophages resulted in hyper-responses
to lipopolysaccharide (LPS; Kinjyo et al., 2002; Hashimoto et al.,
2009; Sachithanandan et al., 2011) and SOCS1-deﬁcient dendritic
cells (DCs) promoted hyperactivation of Th1, lupus-like autoim-
mune diseases, and anti-tumor immunity (Hanada et al., 2003,
2005).
We have demonstrated that SOCS1 plays an essential role in
intestinal immune homeostasis by regulating prostaglandin E2
(PGE2)-mediatedDC andmacrophage suppression (Chinen et al.,
2011). Although SOCS1/Rag2 DKO mice did not die neonatally,
these mice developed severe colitis at 2–6months of age, mostly
due to impairment of the PGE2-mediated anti-inﬂammatory
mechanism. PGE2 has been shown to inhibit TLR signaling by
suppressing NF-kB activity through c-Fos (Koga et al., 2009).
This suppression system is shown to be impaired in SOCS1-
deﬁceint DCs, due to hyperactivation of STAT1 (Figure 2; Chinen
et al., 2011). SOCS1 has been implicated in the mechanism of
glucocorticoid-mediated STAT1 suppression (Haffner et al., 2008;
Bhattacharyya et al., 2011).
SOCS1 AND INFECTION
SOCS1 is also highly upregulated by M. tuberculosis infection
and reduced responses to IL-12, resulting in an impaired IFNγ
secretion by macrophages that in turn accounts for deteriorated
intracellular mycobacterial control. Thus, SOCS1 expression by
macrophages hampered M. tuberculosis clearance early after infec-
tion in vivo in an IFNγ-dependent manner. On the other hand,
at later time points, SOCS1 expression by non-macrophage cells
protected the host from infection-induced detrimental inﬂam-
mation (Carow et al., 2011). Similarly, SOCS1 is highly induced
by Toxoplasma gondii infection, which is a mechanism to escape
from IFNγ action (Stutz et al., 2012). Hepatitis C virus (HCV)
core protein has been shown to impair IL-12 expression in mono-
cytes/macrophages through interaction with a complement recep-
tor gC1qR, which triggers the expression of SOCS1 (Zhang et
al., 2011). SOCS1 is also induced by Ebola virus infection in
macrophages (Okumura et al., 2010). These reports suggest that
SOCS1 is induced in macrophages by various type of infection
FIGURE 2 | Role of SOCS1 and PGE2 in macrophage/dendritic cell
activation.Treg/IL-10/STAT3 and PGE2/cAMP are two independent
anti-inﬂammatory mechanisms, although precise molecular mechanisms
have not been clariﬁed yet. SOCS1 is involved in the cAMP suppression
system but not in the IL-10 system. SOCS1 prevents the breakdown of
cAMP-mediatedTLR signaling by suppressing STAT1. On the other hand,
SOCS3 may keep proper TLR signaling by inhibiting IL-6-mediated STAT3
activation. SOCS3 has no effect on IL-10 mediated anti-inﬂammatory effect.
and inhibits TLR signaling, IL-12 production and IFNγ responses,
which is an important mechanism for microbes to escape from
host immunity.
SOCS3 REGULATES IL-6-MEDAITED PRO- AND ANTI-INFLAMMATORY
REACTION
In contrast to SOCS1, the role of SOCS3 in innate inﬂammation
is complex. SOCS3 deﬁciency in macrophages protects mice from
endotoxemia, because of the reduced production of inﬂamma-
tory cytokines, which is due to the enhanced anti-inﬂammatory
effect of STAT3 (Yasukawa et al., 2003). Furthermore,macrophage-
speciﬁc SOCS3 cKO mice have reduced IL-12 responses and suc-
cumb to toxoplasmosis (Whitmarsh et al., 2011). In the absence of
SOCS3, macrophages are hypersensitive to the anti-inﬂammatory
properties of IL-6. Thus, SOCS3 plays a critical role in suppressing
IL-6 signals and promoting immune responses to control T. gondii
infection (Whitmarsh et al., 2011). On the contrary, mice with a
conditional deletion of SOCS3 in hematopoietic cells have been
shown to develop lethal inﬂammatory disease during adult life
and develop gross histopathological changes during experimen-
tal arthritis, typiﬁed by elevated IL-6 levels (Wong et al., 2006).
Croker et al. reported that acute responses to IL-1β were lethal to
SOCS3 cKOmice but not SOCS3/IL-6-double KOmice, indicating
that loss of SOCS3 is pro-inﬂammatory when IL-6 is required for
inﬂammation. Furthermore, they showed that infection of SOCS3
cKOmicewith LCMV induced a lethal inﬂammatory response that
was dependent on IL-6 (Croker et al., 2012). Therefore, SOCS3 is
probably both pro- and anti-inﬂammatory depending on the pro-
and anti-inﬂammatory action of IL-6.
SOCS3 AND MACROPHAGE POLARIZATION
SOCS3 in macrophages may regulate macrophage polarization.
At least two distinct subpopulations with different functions, the
classically (M1) and the alternatively (M2) activated macrophages,
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have been found (Murray andWynn,2011).Macrophages inwhich
SOCS3was knocked downby short interfering RNApreventedM1
activation, suggesting that SOCS3 is necessary for M1 (Liu et al.,
2008). Wang et al. (2010) reported that forced activation of Notch
signaling in macrophages enhanced M1 polarization and their
anti-tumor capacity through SOCS3 induction. Macrophage-
speciﬁc SOCS3 cKO mice exhibited resistance to the tumor trans-
plantation model because of reduced tumor-promoting cytokines
such as TNFα and IL-6 and enhanced production of anti-
tumorigenic chemokine MCP2/CCL8 (Hiwatashi et al., 2011).
Thus, SOCS3 is an important modulator of macrophage phase
and functions.
SOCS3 AND DCs
SOCS3−/− DCs exhibited constitutive activation of STAT3 and
expressed low levels of MHC class II molecules, co-stimulatory
molecules, and IL-12 (Matsumura et al., 2007). Adoptive trans-
fer of SOCS3−/− DCs suppressed experimental autoimmune
encephalomyelitis (EAE). SOCS3−/− DCs produced a higher
amount of TGF-β than WT DCs, resulting in a selective expan-
sion of forkhead box P3 (FoxP3)-positive regulatory T cells (Tregs).
Thus, in the absence of SOCS3, DCs tends to become tolerogenic
DCs. However, SOCS3-transduced DCs also expressed low levels
of MHC class II and CD86 molecules and produced high lev-
els of IL-10 but low levels of IL-12, IFNγ, and IL-23 p19 (Li
et al., 2006). STAT3 activation was suppressed by SOCS3 over-
expression. Although the mechanism has not yet been clariﬁed,
SOCS3-transduced DCs efﬁciently induced Th2-cell differentia-
tion and suppressed Th17 in vitro and in vivo and the adoptive
transfer of SOCS3-overexpressing DCs suppressed EAE, just like
SOCS3−/− DCs (Li et al., 2006). These results suggest that the sta-
tus of STAT3 activation levels may determine the balance between
Th2 and Tregs induced by DCs.
In addition, SOCS3 is an important negative regulator of gran-
ulopoiesis because SOCS3 negatively regulates the G-CSF receptor
signaling (Croker et al., 2004; Kimura et al., 2004). Mice in which
the SOCS3 gene was deleted in all hematopoietic cells developed
a spectrum of inﬂammatory pathologies with hyper-neutrophilia.
SOCS3-deﬁcient mice developed inﬂammatory neutrophil inﬁl-
tration into multiple tissues and consequent hind-leg paresis
(Wong et al., 2006). SOCS3 has also been shown to inhibit NKT
cell activation (Nakaya et al., 2009).
FUNCTION OF SOCS3 IN NON-IMMUNE CELLS FOR INFLAMMATION
In non-immune cells, SOCS3 suppresses inﬂammatory reactions
by inhibiting STAT3. STAT3 activation is found in epithelial
and lamina propria cells in the colon of mice with intestinal
bowel disease (IBD), as well as in human ulcerative colitis and
Crohn’s disease patients (Suzuki et al., 2001) and in synovial
ﬁbroblasts of RA patients (Shouda et al., 2001). Forced expres-
sion of either SOCS3 or a dominant negative form of STAT3 in
mouse arthritis models suppressed the induction/development
of the disease, indicating that SOCS3 in non-immune cells is
probably anti-inﬂammatory (Shouda et al., 2001). These ﬁnd-
ings are consistent with the idea that the IL-6- and IL-6-related
cytokines-STAT3 pathway promotes chronic disease progression
and SOCS3 is part of this negative-feedback loop (Sawa et al.,
2006 #412). This idea is supported by a recent ﬁnding that the JAK
inhibitor CP-690550 is a potent therapeutic agent for the autoim-
mune arthritismodel by suppressing the IL-6/STAT3 ampliﬁcation
(Mori et al., 2011). However, when STAT3 plays a protective role
for tissue injury, such as in ConA-induced hepatitis, deletion of
SOCS3 is anti-inﬂammatory (Ogata et al., 2006b).
SOCS AND HELPER T CELLS
SOCS1 AND EFFECTOR HELPER T CELLS
We have recently demonstrated that SOCS1 is an essential regu-
lator for helper T cell differentiation. Most SOCS1−/−CD4 naïve
T cells differentiated into Th1, even under Th2 or Th17 skewing
conditions, whereas Th17 differentiation was strongly suppressed
(Tanaka et al., 2008). This was also dependent on IFNγ, because
Th17 was normally developed in SOCS1−/− IFNγ−/− T cells. As
a result, T cell-speciﬁc SOCS1-deﬁcient mice developed autoim-
mune inﬂammatory diseases with age (Takahashi et al., 2011) and
were very sensitive to dextran sulfate sodium (DSS)-induced col-
itis (Horino et al., 2008) and ConA-induced hepatitis (Th1 type
disease;Hashimoto et al., 2011),butwere resistant to EAE,a typical
Th17 type disease (Tanaka et al., 2008).
Th17 suppression by SOCS1 deﬁciency is probably due to the
hyperproduction and signal transduction of IFNγ. Indeed, STAT1
activation in SOCS1−/− T cells was upregulated and strong Th1
skewing was corrected under STAT1+/− conditions (Tanaka et al.,
2008). Interestingly, STAT3 activation was reduced in SOCS1-
deﬁcient T cells, mostly due to the upregulation of SOCS3 gene
expression, which can account for reduced IL-6 responses and
Th17 differentiation. Indeed, SOCS3-tg mice were resistant to
EAE, and Th17 differentiation of SOCS3-tg T cells was sup-
pressed. The reciprocal regulation of Th1 and Th17 by SOCS1
and SOCS3 is illustrated in Figure 3. In addition, SOCS1−/−
T cells were less responsive to TGF-β, although the mechanism
has not yet been clariﬁed. Reduced STAT3 activation and TGF-β
signaling may explain the suppression of Th17 differentiation in
SOCS1-deﬁcient T cells. Our microarray analysis revealed that
T-bet, Eomesodermin, and Gﬁ-1 were upregulated in SOCS1-
deﬁceint T cells under Th17 skewing conditions, all of which have
been reported to suppress Th17 differentiation (Ichiyama et al.,
2009, 2011). Role of SOCS1 and SOCS3 in Th differentiation is
summarized in Figures 3 and 4A.
SOCS1 AND Tregs
Suppressor of cytokine signaling-1 also plays an important role
in the regulation of regulatory T cells. Higher numbers of Tregs
are observed in the thymus and spleen of T cell-speciﬁc SOCS1-
deﬁcient mice (Lu et al., 2009). This is probably due to higher IL-2
responses, because IL-2 enhances the proliferation of Tregs. Impor-
tantly, SOCS1 has been shown to be a target of miRNA-155 in Tregs
(Lu et al., 2009). During thymic differentiation, the upregulation
of Foxp3 drives the high expression of miR155, which in turn pro-
motes the expansion of Treg cells by targeting SOCS1. However,
SOCS1 has recently been found to play more important functional
roles inTregs.Various studies have suggested that Tregs may become
harmful effector T cells in inﬂammatory conditions. Lu et al.
(2010) observed that SOCS1 deletion speciﬁcally in Tregs induced
the development of spontaneous dermatitis, splenomegaly, and
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FIGURE 3 | Role of STATs and SOCS proteins in helperT cell
differentiation.T cell differentiation from naïve cells into the various
functional subtypes (e.g., Th1, Th2, Th17, andTreg cells) primarily depends on
the action of cytokines as indicated. SOCS1 and SOCS3 regulate the cytokine
pathways indicated, and thereby dictate CD4+ T cell differentiation. Note that
SOCS3 inhibits Th1 through overexpression by suppressing IL-12 mediated
STAT4 activation. However, SOCS3 deletion also inhibits Th1 by promoting the
production of IL-10 andTGF-β. In Tregs, SOCS1 deletion promotesTreg
expansion; however, these are functionally impaired. Thus, SOCS1 negatively
regulates theTreg number, but is necessary for the function of Tregs. The role of
SOCS3 in Tregs has not yet been clariﬁed. For Th17, RORγt induction byTGF-β
has been demonstrated to be independent of Smad2/3/4.
FIGURE 4 | Role of SOCS1 and SOCS3 inTh1/Th17 balance (A) and in
nTreg integrity (B). In Th1 conditions, activated STAT1 induces SOCS3
expression, which in turn inhibits STAT3 activity, thereby suppressingTh17
development. In Th17 conditions, SOCS1 is highly expressed and inhibits
IFNγ-mediatedTh1 development. In nTregs, the SOCS1 level is constantly
high, and suppresses STAT1, STAT3, and STAT5 in inﬂammatory conditions
(high levels of cytokines such as IL-2, IL-6, and IFNγ). The higher activation of
STAT5 results in an increase in the number of Tregs, because STAT5 directly
upregulates Foxp3 expression. The higher activation of STAT1 and STAT3
induces loss of Foxp3 expression by unknown mechanisms and promotes
IFNγ and IL-17 production, respectively. Thus, SOCS1 is a “guardian” ofTregs.
lymphadenopathy, suggesting a defective Treg function in these
mice. The defective suppression activity of SOCS1-deﬁcient Tregs
was conﬁrmed through the failure to suppress colitis in Rag2−/−
mice by the co-transfer of naïve T cells and Tregs (Takahashi et al.,
2011). In the absence of SOCS1, Tregs easily lost Foxp3 expres-
sion, and became pathogenic T cells that induced severe colitis (Lu
et al., 2010). In addition, SOCS1 plays an important role in pre-
venting inﬂammatory cytokine production from Tregs. Normally,
Tregs do not secrete inﬂammatory cytokines even in inﬂammatory
conditions. In the absence of SOCS1, Tregs secrete IFNγ and IL-17
by hyperactivation of STAT1 and STAT3, respectively (Takahashi
et al., 2011). Thus, SOCS1 is a “guardian” of Tregs, since SOCS1
inhibits loss of Foxp3 and conversion of Tregs to Th1- or Th17-like
cells (Figure 4B).
ROLE OF SOCS3 IN HELPER T CELLS
The degree to which SOCS3 expression in T cells is increased is
correlated to the severity of human allergic diseases such as asthma
and atopic dermatitis (Seki et al., 2003). The enhanced action of
SOCS3 may promote allergic responses, since transgenic SOCS3
expression in T cells inhibits Th1 development and promotes Th2
development (Seki et al., 2003). Enhanced Th2 development may
be due to the suppression of Th1 because IL-12 mediated Th1 dif-
ferentiation by SOCS3 overexpression. Therefore, SOCS3-tg mice
were sensitive to L. Major infection, where Th1 is necessary for
eradication of this microbe (Nakaya et al., 2011). As described
before, SOCS3-expressing T cells differentiated into Th17 cells
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less efﬁciently than WT T cells (Tanaka et al., 2008). In contrast,
mice lacking SOCS3 in T cells result in reduced allergen-induced
eosinophilia in the airways (Kinjyo et al., 2006; Figure 3). SOCS3
silencing with small interfering RNA (siRNA) in primary CD4+
T cells attenuated the Th2 response in vitro and in vivo (Moriwaki
et al., 2011). SOCS3 deﬁciency promoted Th17 differentiation in
T cells (Chen et al., 2006). Using VavCre-SOCS3 cKO mice, Wong
et al. (2006) reported that the IL-1-induced inﬂammatory joint
disease model was severely deteriorated in the absence of SOCS3
accompanying the enhanced IL-17 production fromCD4+T cells.
SOCS3deﬁciency inT cells reduced atherosclerotic lesiondevelop-
ment and vascular inﬂammation, which was dependent on IL-17,
whereas the overexpression of SOCS3 in T cells reduced IL-17
and accelerated atherosclerosis (Taleb et al., 2009). The absence of
SOCS3 inhelperT cells therefore generally inhibits Th1 andTh2by
producing IL-10 and TGF-β, but had dramatic pro-inﬂammatory
effects under Th17 conditions (Tamiya et al., 2011). Recently,
leukemia inhibitory factor (LIF) has been shown to inhibit Th17
differentiation by inducing SOCS3 (Cao et al., 2011). The para-
doxical effect of SOCS3 on T cell regulation is mostly due to
the dual function of STAT3; it promotes the production of both
inﬂammatory IL-17 and anti-inﬂammatory IL-10 and TGF-β.
In the LCMC clone 13 infection model, SOCS3 is highly
induced inT cells, andT cell-speciﬁc SOCS3-deﬁcientmice exhibit
a profound augmentation of immunity and are protected from
severe organ pathology, with an increase in the number of virus-
speciﬁc CD8+T cells and an increase in the ability of CD4+T
cells to secrete TNF-α and IL-17. This T cell-intrinsic SOCS3
induction has been implicated as a major factor contributing to
immunological failure in the setting of chronic active infection
(Pellegrini et al., 2011).
SOCS AND HUMAN INFLAMMATORY DISEASES
It has been estimated that more than 20% of all malignancies
are initiated or exacerbated by inﬂammation; for example, most
human hepatocellular carcinomas (HCCs) are a consequence of
HCV infection (Yoshimura, 2006). The expression of SOCS1 is
often silenced in these tumors by hypermethylation of CpG islands
including HCCs.We found that silencing of SOCS1 was frequently
observed even in pre-malignant HCV-infected patients (Yoshida
et al., 2004). Liver injury is associated with hyperactivation of
STAT1 and reduced activation of STAT3. Therefore, the reduced
expression of SOCS1 may enhance tissue injury and inﬂammation
through the hyperactivation of STAT1, promoting the turnover of
epithelial cells and enhancing their susceptibility to oncogenesis.
Therefore, SOCS1 is a unique anti-oncogene that prevents car-
cinogenesis by suppressing chronic inﬂammation (Hanada et al.,
2006; Torisu et al., 2008).
SOCS3 may also be involved in the development and progres-
sion of malignancies. SOCS3 expression levels were reduced in
tumor areas of patients infected with HCV compared with non-
tumor regions (Ogata et al., 2006b). Hyperactivation of STAT3 by
SOCS3 repression may contribute to tumorigenesis by inducing
multiple tumor-promoting genes (Ogata et al., 2006a).
As mentioned before, levels of SOCS3 in T cells are correlated
to allergic diseases (Seki et al., 2003). Several genomic SNPs in the
human SOCS1 gene were found to be associated with serum IgE
levels (Mostecki et al., 2011), asthma (Harada et al., 2007), and
leukemia (Guillem et al., 2012). SOCS1 mutations were found in
human lymphomas (Mottok et al., 2009).
CONCLUDING REMARKS
Over the past decade, following the discovery of the SOCS pro-
tein families, we have extended our understanding of the struc-
ture and function of these proteins. SOCS proteins act as simple
negative-feedback regulators, and they also play a part in the ﬁne
tuning of the immune response and inﬂammation. Therapeutic
trials using SOCS anti-sense oligonucleotides, shRNA, and pep-
tide mimetics are currently underway in animal models. SOCS1
and SOCS3 are ideal therapeutic targets for autoimmune diseases
and inﬂammatory diseases, including cancer.
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